OVERALL SURVIVAL IN PATIENTS WITH ENDOMETRIAL CANCER TREATED WITH DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL IN THE RANDOMIZED ENGOT-EN6/GOG-3031/RUBY TRIAL.

LORLATINIB VERSUS CRIZOTINIB IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: 5-YEAR OUTCOMES FROM THE PHASE III CROWN STUDY

TRASTUZUMAB PLUS GEMCITABINE-CISPLATIN FOR TREATMENT-NAïVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BILIARY TRACT ADENOCARCINOMA: A MULTICENTER, OPEN-LABEL, PHASE II STUDY (TAB)

REGOMA-OSS: A LARGE, ITALIAN, MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF REGORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.

ELACESTRANT (ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY FOR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER: RESULTS FROM THE RANDOMIZED PHASE III EMERALD TRIAL.